- Home
- IMCR vs DGNX Comparison
IMCR vs DGNX Comparison
Compare IMCR & DGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- DGNX
- Stock Information
- Founded
- IMCR 2008
- DGNX 2018
- Country
- IMCR United Kingdom
- DGNX United Kingdom
- Employees
- IMCR N/A
- DGNX N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- DGNX
- Sector
- IMCR Health Care
- DGNX
- Exchange
- IMCR Nasdaq
- DGNX NYSE
- Market Cap
- IMCR 1.7B
- DGNX 1.4B
- IPO Year
- IMCR 2021
- DGNX 2025
- Fundamental
- Price
- IMCR $35.17
- DGNX $51.23
- Analyst Decision
- IMCR Buy
- DGNX
- Analyst Count
- IMCR 10
- DGNX 0
- Target Price
- IMCR $58.13
- DGNX N/A
- AVG Volume (30 Days)
- IMCR 250.5K
- DGNX 41.2K
- Earning Date
- IMCR 08-07-2025
- DGNX 01-01-0001
- Dividend Yield
- IMCR N/A
- DGNX N/A
- EPS Growth
- IMCR N/A
- DGNX N/A
- EPS
- IMCR N/A
- DGNX N/A
- Revenue
- IMCR $333,581,000.00
- DGNX $2,040,602.00
- Revenue This Year
- IMCR $26.82
- DGNX N/A
- Revenue Next Year
- IMCR $8.15
- DGNX N/A
- P/E Ratio
- IMCR N/A
- DGNX N/A
- Revenue Growth
- IMCR 25.75
- DGNX 57.02
- 52 Week Low
- IMCR $23.15
- DGNX $3.60
- 52 Week High
- IMCR $40.88
- DGNX $155.00
- Technical
- Relative Strength Index (RSI)
- IMCR 53.52
- DGNX N/A
- Support Level
- IMCR $32.20
- DGNX N/A
- Resistance Level
- IMCR $37.63
- DGNX N/A
- Average True Range (ATR)
- IMCR 1.21
- DGNX 0.00
- MACD
- IMCR 0.03
- DGNX 0.00
- Stochastic Oscillator
- IMCR 53.90
- DGNX 0.00
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About DGNX DIGINEX LIMITED
Diginex Ltd is an investment holding company. It engaged in providing Environmental, Social, and Governance (ESG) reporting solution services, advisory services, and developing customization solutions. It is a sustainable RegTech business that empowers businesses and governments to streamline ESG, climate, and supply chain data collection and reporting. The company utilizes blockchain, AI, machine learning, and data analysis technology to change and increase corporate regulatory reporting and sustainable finance transparency. Its solutions and services enable companies to collect, evaluate, and share sustainability data through easy-to-use software.